Rhythm Pharmaceuticals Eyes March 20 Approval After 19.8% BMI Drop in HO Study
Rhythm reported Q3 IMCIVREE sales of $57 million, up roughly 9% quarter-over-quarter, with patient access in 25 countries and $418 million cash providing a 24-month runway. The company has expanded its U.S. sales force from 16 to 42 ahead of a March 20 PDUFA for hypothalamic obesity showing ~19.8% BMI reduction.
1. Q3 Commercial Performance
Rhythm reported Q3 IMCIVREE sales of $57 million, marking approximately 9% quarter-over-quarter growth driven by Bardet-Biedl syndrome prescriptions. The therapy now has approval, reimbursement or patient access in 25 countries, with a 10% increase in reimbursed patients and a 7% rise in prescribers during Q4.
2. HO Indication and PDUFA Timeline
The company is set for a March 20 PDUFA decision on hypothalamic obesity, based on a 60-week randomized trial showing a 16.5% BMI reduction versus placebo weight gain, yielding a placebo-adjusted ~19.8% BMI drop. Responders included 80% achieving over 5% weight loss and 60% achieving over 10%, supporting the new indication.
3. Sales Force Expansion and Patient Identification
Rhythm expanded its U.S. commercial team from 16 to 42 representatives by October to prepare for HO launch. Using a claims-based algorithm targeting tumor events, endocrine insufficiency and obesity codes, the company identified roughly 2,000 suspected hypothalamic obesity patients across tier one and two practices.
4. Financial Runway and Pipeline Progress
The company exited Q3 with $418 million in cash, securing at least a 24-month operating runway. Pipeline initiatives include a Prader-Willi syndrome Phase 2 six-month readout in H1, exploration of VICAD combinations, and development of oral bivamelagon and weekly injectable RM-718.